Autolus Therapeutics PLC (NASDAQ: AUTL) made headlines today as the stock moved 2.4% and is currently trading at $6.95 per share. The company announced the appointment of Robert W. Azelby to its board of directors. Dr. Christian Itin, CEO of Autolus, expressed his enthusiasm about Azelby's appointment, stating, "Bob brings with him a wealth of experience and a strong track record in building successful biotech companies and his extensive commercial experience will be invaluable as we get closer to commercializing our first product."
In response to his appointment, Mr. Azelby commented, "It's an exciting time to be joining Autolus with a BLA filing having recently been submitted for the company's lead CAR T cell therapy, obe-cel. I look forward to helping Autolus leverage its strengths as it moves from a development stage to a commercial company."
Azelby brings over 30 years of biopharmaceutical leadership and commercial experience to Autolus's board. He has held significant roles in various biotech companies, including his recent position as President and CEO of Eliem Therapeutics Inc., and prior roles at Alder Biopharmaceuticals, Inc. and Juno Therapeutics, Inc.
Autolus is a clinical-stage biopharmaceutical company focused on developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. The company utilizes proprietary and modular T cell programming technologies to engineer precisely targeted, controlled, and highly active T cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases.
For the full press release, including the company's 8-K submission, click here.
